Multifors 3: INFORS HT 23-day perfusion culture specs

INFORS HT Switzerland

Overview

INFORS HT has published an application note detailing the successful 23-day long-term perfusion culture of NIST CHO cells using its Multifors 3 benchtop bioreactor. The study proves the Multifors 3’s suitability for extended perfusion processes and its integrated control capabilities for critical bioreactor variables, including gravimetric volume control, feeding rates, pH, dissolved oxygen, and biomass. This achievement underscores the Multifors 3’s robustness for continuous bioprocessing applications and its significance in accelerating biopharmaceutical process development.

In Depth

Key Findings

INFORS HT has announced a significant achievement in bioprocess development, publishing an application note detailing the successful, stable long-term perfusion cultivation of NIST CHO cells over 23 days using their Multifors 3 benchtop bioreactor. This demonstration unequivocally validates the Multifors 3 system’s robust performance and integrated control capabilities for continuous bioprocessing applications at the process development scale.

Technical / Clinical Details

The perfusion culture study utilized a standard CHO cell line sourced from the National Institute of Standards and Technology (NIST). The Multifors 3 bioreactor system showcased its advanced capability to integrate and precisely control key culture parameters, including gravimetric volume control, feeding rates, pH, dissolved oxygen (DO), and biomass concentration. Over the extended 23-day period, the cells maintained high viability and productivity, demonstrating the system’s ability to sustain a stable perfusion process. This performance is critical for continuous biopharmaceutical production, where consistent culture conditions are paramount. The data presented reinforces the Multifors 3’s versatility and reliability for a wide range of applications, from early-stage research to initial process optimization phases.

Background & Context

In the biopharmaceutical industry, there is a strong and growing trend towards process intensification and the adoption of continuous manufacturing for monoclonal antibodies and other recombinant proteins. Perfusion culture is central to this trend, enabling high cell densities, maximizing product yields, and simultaneously reducing the burden on downstream purification processes. However, the stable and long-term operation of perfusion processes demands sophisticated bioreactor control technology. The INFORS HT Multifors 3 is positioned as a key solution addressing these requirements at the benchtop scale, providing a robust platform for efficient process development.

Strategic Significance & Outlook

The successful demonstration of long-term perfusion culture with NIST CHO cells using the Multifors 3 bioreactor holds significant implications for accelerating biopharmaceutical development. Researchers and engineers can now rely on a highly dependable benchtop system to rapidly optimize continuous production processes. This is expected to lead to shorter time-to-market for new drugs and substantial reductions in manufacturing costs. Furthermore, this technology serves as a vital bridge to future GMP scale-up, accelerating the broader adoption of continuous manufacturing techniques throughout the biopharmaceutical industry. INFORS HT is poised to strengthen its leadership in providing advanced bioprocess solutions.

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.

• Your email and selected fields are used only to deliver the newsletter.
• We never share your information with third parties.
• You can unsubscribe anytime via the link in each email.

See our Privacy Policy for details.

Agree & Continue ▶

Takes about a minute · Unsubscribe anytime